All News
IV Secukinumab for AxSpa
The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis. Data for this new approval will be presented at ACR Convergence on November 14th by Dr. Atul Deodhar.
Read Article
Amazing & thoughtful poster re:protocol violates in TICOSPA trial
51.2% of pts violated T2T protocol at least once... but did not impact primary outcome
Good baseline for future "strategy" style pragmatic trials
@RheumNow #ACR23 #ACRBest Abstr2201 https://t.co/FhctgFNdNP
Mike Putman EBRheum ( View Tweet)
CV Events in AS by Rx
A#L11 @RheumNow #ACR23
43K pts from Korean data
Rates of incident MI or CV:
18.7 per 10,000 py in non-bDMARD pt
8.9 in TNF
12.9 in IL-17
TNFi reduced risk of CVD HR 0.7, not signif for IL-17
Supports idea of TNFi giving a cardioprotective effect?
#ACRBest https://t.co/SvVVDSU23z
Eric Dein ( View Tweet)
Real-World Issues in AxSpA: Treatment Intensification, Pregnancy
Dr. Rabab Nezam El-Din and colleagues explored patient- and disease-related determinants that were associated with treatment intensification among axSpA patients w/ high disease activity.
https://t.co/vZ66hsErBI https://t.co/pN8JZAEcqv
Dr. John Cush RheumNow ( View Tweet)
Be a SpA (and PsA) Sleuth! My article is your call to arms for better understanding and discovery of IBD in our inflammatory back pain patients. Consider fecal calprotectin AND robust ROS as your magnifying glass! #ACR23 @rheumnow https://t.co/OnQDEWgIWM
Dr. Rachel Tate ( View Tweet)
From patient to research/clinical rheumatologist and SpA advocate. Check out my #ACR23 interview with Dr. Hillary Norton. @DrHillaryNorton @RheumNow https://t.co/SeZeqb8wid
Dr. Rachel Tate ( View Tweet)
Dr. Alexis Ogdie updates me on her #ACR23 must knows for SpA/PsA patients @RheumNow https://t.co/hFLzLtmcSl
Dr. Rachel Tate ( View Tweet)
Went into more depth on this great topic of IBD in SpA on @RheumNow #ACR23
Should we be screening SpA patients with fecal calprotectin to look for undiagnosed SpA?
https://t.co/TmXhm2MEfO https://t.co/SWJSqF5pkW
Eric Dein ( View Tweet)
#irAE Baseline immune suppression does NOT protect against worsening synovitis flares when using check point inhibitors in Pts with established #inflammatory #arthritis #ACRbest #ACR23 @ACRheum @RheumNow abst1075 Data from #CanRIO database https://t.co/lOCf8Tbgta
Janet Pope ( View Tweet)
#ACR23 Abs #2199 large RL study: SEC retention rates after 4 yrs approx. 50% in axSpA and PsA pts. Bio-naïve pts had higher retention, remission & response rates than pts with prior b/tsDMARD exposure, particularly in axSpA. https://t.co/Eq5BwILK3D @rheumnow https://t.co/slho6yAwtQ
Dr. Rachel Tate ( View Tweet)
SPARTAN referral recommendations for axSpA #ACR23 Abs #2214 https://t.co/VQedpNynpv support Abs #2207 https://t.co/8RB0D4ef7i findings discussing that non-rheums are less aware of IBP components/asking about them in CBP pts. @rheumnow https://t.co/23oUONsMfb
Dr. Rachel Tate ( View Tweet)
The presence of antibodies to 4 UH-axSpA peptides was confirmed in the Belgian Inflammatory Arthritis and Spondylitis (Be-Giant) cohort of newly diagnosed axSpA patients and could be of added value for axSpA diagnosis. #ACR23 Abs #2210 https://t.co/fV4PPbWF01 @rheumnow
Dr. Rachel Tate ( View Tweet)
A#1403 #ACR23 @RheumNow
17% of 1st degree relatives of AS pts have MRI-defined sacroiliitis
Study of 100 subjects w FHx AS
- 13/100: new dx of AxSpA, 7 w radiographic changes
- 4/100: Sacroiliitis without back pain
- 1 periph SpA
- 12 met clinical ASAS classification but not dx https://t.co/V7LCbaDXBe
Eric Dein ( View Tweet)
17% of 1st degree relatives AS pts had MRI- defined sacroiliitis, however not all of them were diagnosed w/ SpA due to absence of back pain. 25% w/ 1st degree AS relative met the classification criteria for SpA #ACR23 Abs #1403 https://t.co/W1T9ZqD4o1 @rheumnow https://t.co/DnaNSLiqfU
Dr. Rachel Tate ( View Tweet)
Does NSAID use = CKD?
Large Korean study on CKD in ankylosing spondylitis pts showed risk of CKD associated with comorbidities.
Long term NSAID use not associated with increased risk of CKD.
@RheumNow #ACR23 Abs#1394 https://t.co/m3kYI30gBc
Robert B Chao, MD ( View Tweet)
Risk of CKD in AS patients was associated with comorbidities, not NSAID use. #ACR23 Abs #1394 https://t.co/cbOPvjOCyq @rheumnow https://t.co/O0rhbMFiOX
Dr. Rachel Tate ( View Tweet)
Majority of pts with axSpA had below avg aerobic capacity indicating high risk of morbidity.
Importance of supporting pts with axSpA to lead healthy lifestyle and improved aerobic capacity by exercise!
@RheumNow #ACR23 Abs#1395 https://t.co/SFAStGQaK0
Robert B Chao, MD ( View Tweet)
What if you have a first degree relative with ankylosing spondylitis?
100 pts w/o previous rheum dx w/ 1st degree AS relative
17% had MRI sacroiliitis
25% met classification criteria
14% dx with AS
@RheumNow #ACR23 Abs#1403 https://t.co/Z0juhRnLki
Robert B Chao, MD ( View Tweet)
15-year results from Abs #1389 at #ACR23 found only low back pain to be predictor of spinal radiographic progression in axSpA pts. Mean and median progression changes by mSASSS per year less in this cohort than previously documented. https://t.co/VKTEZWvH7f @rheumnow https://t.co/6sjPrcw2dD
Dr. Rachel Tate ( View Tweet)
Biologics are working for ankylosing spondylitis, even in reducing cardiovascular mortality!
Large retrospective study of over 4k pts over 20 years showed decrease in CV mortality from 34% in 1999 to 21% in 2020
@RheumNow #ACR23 Abs#1399
#ACRbest https://t.co/wKCIXHza0v
Robert B Chao, MD ( View Tweet)
